Patterns of selective neuronal damage in methamphetamine-user AIDS patients

Area of Science:

• Neuroscience
• Infectious Diseases
• Toxicology

Background:

• Methamphetamine (METH) use is rising among HIV-positive individuals.
• The neuropathogenesis of HIV encephalitis (HIVE) in the context of METH use remains poorly understood.

Purpose of the Study:

• To investigate the neuropathological differences between HIV-positive METH users and non-users with HIVE.
• To elucidate the specific patterns of neurodegeneration induced by the combined effects of HIV and METH.

Main Methods:

• Neuromedical and postmortem neuropathological examinations of HIV-positive patients.
• Immunocytochemical and polymerase chain reaction analyses to assess brain HIV levels and rule out other viral infections.
• Evaluation of neurodegeneration markers including gp41, synaptophysin, calbindin (CB), and microglial reactions.

Main Results:

• METH users with HIVE exhibited less severe encephalitis but more ischemic events and microglial reactions.
• A significant loss of calbindin (CB)-immunoreactive interneurons with aberrant sprouting was observed in METH-using patients.
• Reduced gp41 scores and synaptophysin immunoreactivity were noted in METH users compared to non-users.

Conclusions:

• Combined METH and HIV infection selectively damages calbindin (CB)-immunoreactive nonpyramidal neurons.
• METH and HIV synergistically enhance neuronal injury and death, potentially worsening brain metabolic disturbances in affected individuals.
• Findings highlight the critical impact of METH on HIV-associated neurodegeneration.